Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 50% less
These brands contain the same active ingredient (Ziprasidone). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Zipradon is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Administer capsules by mouth with food, and do not open, crush, or chew them. For schizophrenia: begin at 20 mg twice daily. The daily dose may be adjusted up to 80 mg twice daily, with adjustments made no more often than every 2 days. Doses up to 100 mg twice daily have been shown to be safe and effective, but the lowest effective dose should always be used. For acute treatment of manic or mixed episodes of bipolar I disorder: begin at 40 mg twice daily, increasing to 60 mg or 80 mg twice daily on the second day of treatment. Further adjustments should be guided by tolerability and response, within a range of 40 mg to 80 mg twice daily. For maintenance treatment of bipolar I disorder as an add on to lithium or valproate: continue at the same dose at which the patient was originally stabilized, within a range of 40 mg to 80 mg twice daily. For acute treatment of agitation associated with schizophrenia, given by intramuscular injection: 10 mg to 20 mg as needed, up to a maximum of 40 mg per day. A 10 mg dose may be repeated every 2 hours, and a 20 mg dose may be repeated every 4 hours.
Side Effects
Commonly reported side effects (occurring in 5% or more of patients and at least twice as often as with placebo) included the following. For schizophrenia: sleepiness and respiratory tract infection. For manic and mixed episodes associated with bipolar disorder: sleepiness, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, weakness, and vomiting. For intramuscular administration (occurring in 5% or more of patients and at least twice as often as in the lowest-dose intramuscular Zipradon group): headache, nausea, and sleepiness.
Cautions & Contraindications
Warnings & Precautions
Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack).QT Interval Prolongation: Zipradon use should be avoided in patients with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation.Neuroleptic Malignant Syndrome (NMS): Potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring.Severe Cutaneous Adverse Reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome has been reported with Zipradon exposure. DRESS and other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal. Discontinue Zipradon if DRESS or SCAR are suspected.Tardive Dyskinesia: May develop acutely or chronically.Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.Hyperglycemia and Diabetes Mellitus (DM): Monitor all patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients with DM risk factors should undergo blood glucose testing before and during treatment.Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.Weight Gain: Weight gain has been reported. Monitor weight gain.Rash: Discontinue in patients who develop a rash without an identified cause.Orthostatic Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease.Leukopenia, Neutropenia, and Agranulocytosis has been reported with antipsychotics. Patients with a pre existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Zipradon at the first sign of a decline in WBC in the absence of other causative factors.Seizures: Use cautiously in patients with a history of seizures or with conditions that lower seizure threshold.Potential for Cognitive and Motor impairment: Patients should use caution when operating machinery.Suicide: Closely supervise high-risk patients.
Contraindications
Do not use ziprasidone in patients with a known history of QT prolongation, a recent acute myocardial infarction, or uncompensated heart failure. It should also be avoided in combination with other drugs known to prolong the QT interval, and in anyone with known hypersensitivity to ziprasidone.